CTKB at a glance
Cytek Biosciences, Inc. (CTKB, SEC CIK 1831915) filed its latest 10-K annual report on February 26, 2026, a 10-Q quarterly report on August 5, 2026, an 8-K current report on September 29, 2026 and Form 4 insider filings as recently as August 20, 2026. SignalX summarizes each filing with AI and tracks the company's insider trades and institutional holders.
- For the fiscal year ended December 31, 2025 (FY2025), Cytek Biosciences, Inc. (CTKB) reported revenue of $201.5 million (up 0.5% from FY2024) and a net loss of $66.5 million.
- As of June 30, 2026, 28 institutional investment managers tracked by SignalX reported holding Cytek Biosciences, Inc. (CTKB) shares worth $177.5 million in 13F-HR filings.
Source: SEC EDGAR (XBRL financial data, 13F-HR and Form 4 filings).
- Revenue · FY2025
- $201.5M
- +0.5% vs prior year
- Insiders · 90 days
- 0 buys · 0 sells
- No open-market trades
- 13F holders
- 28 funds
- $177.5M · −2 vs prior quarter
- Latest 8-K
- Sep 29, 2026
- Item 5.03
AI 10-Q Quarterly Report Analysis
Latest 10-Q, quarter ended Jun 30, 2026
Risk Factors
- New product-development risk triggered by June 2026 Cytek Borealis early-access launch
- Most materially updated trade risk: U.S. tariffs on Singapore and China imports increased from 10% to 12.5%
- Regulatory compliance exposure: foreign distributor activity may implicate FCPA books-and-records and anti-bribery provisions
- Near-term operational risk: sole-source lasers and semiconductors require 12–24 months or longer for replacement qualification
- Financial risk: instrument sales cycles extending up to six months or longer drive quarterly revenue volatility
AI summary of the CTKB 10-Q filed . Generated from the filing text; verify against the original.View on SEC EDGAR10-K vs 10-Q vs 8-K
AI 8-K Current Report Analysis
The most recent material events, by 8-K item
Item 5.03: Amendments to Articles of Incorporation or Bylaws
- A&R Bylaws effective September 23, 2026, adopted unanimously by the board
- Expanded disclosure, ownership, solicitation and certification requirements for stockholder proposals and director nominees
Item 7.01: Regulation FD Disclosure
- Exhibit 99.1 furnished under Regulation FD, but excluded from Section 18 “filed” status
- Information generally not incorporated into other Securities Act or Exchange Act filings by reference
Item 8.01: Other Events
- Jury verdict favored Cytek on three of four asserted Beckman Coulter patent claims
- $20 million lost-profit award and $36.11 million royalty award for one claim
Item 2.02: Results of Operations and Financial Condition
- Q2 2026 results for quarter ended June 30, 2026
- Press release furnished as Exhibit 99.1 with detailed financial results
Item EX-99.1: Item EX-99.1
- Q2 revenue $48.1M, up 6%, with instrument growth in the U.S. and China plus continued service expansion
- Gross margin rose to 59% from 52%, but excluding a one-time tariff refund was 53%
AI summaries of CTKB 8-K current reports filed with the SEC. What 8-K item codes mean
SignalX for CTKB
Don't miss the next CTKB filing
- Alerts as it files. A push when CTKB files an 8-K or an insider trades.
- Fund moves. Which tracked funds opened, added or cut CTKB, by share count.
- Ask anything. An AI agent that reads every CTKB filing and answers with sources.
CTKB alerts on your phone. Follow it in the SignalX Android app.
Recent Insider Transactions (Form 4)
Latest reported trades by officers, directors and 10% owners
| Insider | Type | Date | Shares | Price |
|---|---|---|---|---|
| MUIR GLENN P | M | Aug 18, 2026 | 3,086 | - |
| Yan Ming | M | Aug 18, 2026 | 5,525 | - |
| MUIR GLENN P | M | Aug 18, 2026 | 3,086 | - |
| Chin Richard | M | Aug 18, 2026 | 6,107 | - |
| Yan Ming | F | Aug 18, 2026 | 1,778 | $4.67 |
| Yan Ming | M | Aug 18, 2026 | 7,363 | - |
| Holder Michael | M | Aug 18, 2026 | 2,181 | - |
| Holder Michael | M | Aug 18, 2026 | 2,181 | - |
Financial SummaryXBRL
| Metric | FY2023 | FY2024 | FY2025 |
|---|---|---|---|
| Profitability | |||
| Revenue | $193.0M | $200.5M | $201.5M |
| Gross Profit | - | $111.1M | $104.5M |
| Operating Income | - | -$20.5M | -$40.4M |
| Net Income | - | -$6.0M | -$66.5M |
| Gross Margin | - | 55.4% | 51.8% |
| Op. Margin | - | -10.2% | -20.0% |
| Net Margin | - | -3.0% | -33.0% |
| Balance Sheet | |||
| Total Assets | $494.5M | $499.5M | $461.5M |
| Equity | $393.1M | $395.7M | $341.7M |
| ROE | - | -1.5% | -19.5% |
| Cash Flow | |||
| Operating CF | - | $25.4M | -$4.7M |
| CapEx | $4.6M | $3.5M | $4.1M |
Source: XBRL data in Cytek Biosciences, Inc. (CTKB)'s 10-K filings on SEC EDGAR, in USD. Compare across companies →
13F Fund Holdings: Quarterly Trend
Latest: Q2 2026Aggregate CTKB share value held by 13F filers tracked by SignalX, by quarter.
Quarterly totals table
| Quarter | Funds | Total value |
|---|---|---|
| Q2 2026 | 28 | $177.5M |
| Q1 2026 | 30 | $211.1M |
| Q4 2025 | 28 | $233.3M |
| Q3 2025 | 28 | $153.1M |
| Q2 2025 | 26 | $145.4M |
| Q1 2025 | 23 | $105.0M |
| Q4 2024 | 20 | $154.4M |
| Q3 2024 | 17 | $53.8M |
- Millennium Management+3.05M (+48%)
- D.E. Shaw & Co+409.1K (+157%)
- Bank of America Corp+306.3K (+30%)
- Citadel Advisors LLC+250.1K (+53%)
- FMR LLC (Fidelity)+221.0K (+78%)
- BlackRock−7.43M (-44%)
- State Street Corp−1.56M (-38%)
- Vanguard Portfolio Management LLC−1.17M (-51%)
- Morgan Stanley−1.02M (-59%)
- BNY Mellon−237.2K (-39%)
- Principal Financial Group−534.8K
- M&T Bank−10.3K
Source: 13F-HR filings on SEC EDGAR (aggregated from 200 fund-quarter rows). Reflects only 13F filers tracked by SignalX, not the full institutional ownership universe. How 13F filings work
CTKB filing archive
AI analysis pages for each 10-K, 10-Q and 8-K
Latest 2026 SEC Filings: 10-K, 10-Q, 8-K & Form 4
| Form | Filing date | Period | Analysis | SEC |
|---|---|---|---|---|
| 8-K | Sep 29, 2026 | - | Analysis | - |
| 8-K | Aug 24, 2026 | - | Analysis | - |
| 4 | Aug 20, 2026 | - | - | - |
| 4 | Aug 20, 2026 | - | - | - |
| 4 | Aug 20, 2026 | - | - | - |
| 4 | Aug 20, 2026 | - | - | - |
| 4 | Aug 20, 2026 | - | - | - |
| 4 | Aug 20, 2026 | - | - | - |
| 4 | Aug 12, 2026 | - | - | - |
| 10-Q | Aug 5, 2026 | Jun 30, 2026 | Analysis | |
| 8-K | Aug 5, 2026 | - | Analysis | - |
| SC 13G | Aug 4, 2026 | - | - | |
| 8-K | Jul 15, 2026 | - | Analysis | - |
| 8-K | Jun 25, 2026 | - | Analysis | - |
| 4 | Jun 16, 2026 | - | - | - |
| 8-K | Jun 16, 2026 | - | Analysis | - |
| 4 | Jun 12, 2026 | - | - | - |
| 4 | Jun 12, 2026 | - | - | - |
| 4 | Jun 12, 2026 | - | - | - |
| 4 | Jun 12, 2026 | - | - | - |
| 4 | Jun 12, 2026 | - | - | - |
| 4 | Jun 12, 2026 | - | - | - |
| 8-K | Jun 2, 2026 | - | Analysis | |
| 4 | May 20, 2026 | - | - | |
| 4 | May 20, 2026 | - | - |
Related Health Care companies
- TXG · 10x Genomics, Inc.Laboratory Analytical Instruments
- A · Agilent TechnologiesLaboratory Analytical Instruments
- ALMR · Alamar Biosciences IncLaboratory Analytical Instruments
- AVTR · Avantor IncLaboratory Analytical Instruments
- BIO · Bio-rad Laboratories IncLaboratory Analytical Instruments
- BRKR · Bruker CorpLaboratory Analytical Instruments
- EYPT · EyePoint, Inc.Laboratory Analytical Instruments
- ILMN · Illumina IncLaboratory Analytical Instruments
CTKB SEC filings: frequently asked questions
Which institutions hold CTKB stock?
As of June 30, 2026, the largest Cytek Biosciences, Inc. (CTKB) holders among the 13F filers tracked by SignalX were BlackRock ($42.4 million), Millennium Management ($41.4 million), Vanguard Capital Management LLC ($21.9 million), Dimensional Fund Advisors ($11.6 million), State Street Corp ($11.4 million). 13F-HR reports are filed up to 45 days after each quarter ends.
What was CTKB's revenue in fiscal year 2025?
For the fiscal year ended December 31, 2025 (FY2025), Cytek Biosciences, Inc. (CTKB) reported revenue of $201.5 million (up 0.5% from FY2024) and a net loss of $66.5 million. The figures come from the XBRL data in the 10-K.
What did CTKB report in its latest 8-K?
Cytek Biosciences, Inc. (CTKB) filed an 8-K on September 29, 2026 reporting Item 5.03 (Amendments to Articles of Incorporation or Bylaws). A&R Bylaws effective September 23, 2026, adopted unanimously by the board.
What are the latest CTKB SEC filings?
Cytek Biosciences, Inc. (CTKB) filed its latest 10-K annual report on February 26, 2026, a 10-Q quarterly report on August 5, 2026, an 8-K current report on September 29, 2026 and a Form 4 insider filing on August 20, 2026.
What is CTKB's SEC CIK number?
Cytek Biosciences, Inc. (CTKB)'s SEC Central Index Key (CIK) is 1831915. EDGAR lists every CTKB filing under that number.
Ask anything about CTKB
The research agent reads CTKB's filings, financials, insider trades and 13F holders, then answers with sources.